Baraclude is an antiviral medication that contains entecavir and is used primarily for chronic hepatitis b infection. It belongs to the class of nucleos(t)ide reverse transcriptase inhibitors that target the hepatitis b virus polymerase enzyme. The drug inhibits viral dna synthesis by binding to the viral polymerase active site and preventing the formation of new viral genomes. By reducing viral replication, Baraclude lowers the amount of virus in the bloodstream and decreases liver inflammation. This reduction can improve liver function and lower the risk of disease progression to cirrhosis or hepatocellular carcinoma. The medication is taken orally in tablet form and does not require interferon or additional immune modulators. Its effect is specific to infected liver cells, leading to a selective antiviral action without significant impact on normal cells. The cumulative result is a sustained suppression of hepatitis b virus activity and long term disease control.

Baraclude is an antiviral medication used to treat chronic hepatitis b infection. Its active ingredient is entecavir, a nucleoside analog that mimics guanosine. Once administered, entecavir is phosphorylated intracellularly to form active triphosphate metabolites. These metabolites inhibit the viral dna polymerase enzyme, blocking the synthesis of viral dna. By preventing viral replication, Baraclude reduces liver inflammation and slows disease progression. The drug selectively targets viral enzymes with minimal effect on host nucleic acid synthesis. Its pharmacological profile includes high potency, low resistance potential, and favorable hepatic metabolism. Consequently, Baraclude provides long-term viral suppression and improves patient outcomes in chronic hepatitis b.

Baraclude may cause nausea in some patients. Headache is another frequently reported symptom. Fatigue can occur during treatment. Abdominal discomfort such as pain or dyspepsia is also noted. Some individuals experience dizziness. Skin reactions like rash may develop. Elevated liver enzyme levels are sometimes observed in blood tests.

Baraclude may cause headache and fatigue in some patients. Nausea and abdominal discomfort are also reported side effects. Elevated liver enzymes can occur, requiring monitoring during treatment. Dizziness and mild skin rash are additional common reactions. Some users experience joint pain and appetite loss while on the medication. Most of these effects are mild to moderate and often improve with continued use.